CDKN2A and astrocytoma (excluding glioblastoma): Accordingly, in astrocytomas, CDKN2A/B homozygous deletion is now recognized as a molecular criterion for grade 4 designation, even in the absence of histological markers such as necrosis or microvascular proliferation [3].